Carmila SA (CARM)
Euronext Paris · France · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 14.44 |
|---|---|
| 52-week range | 13.98 – 18.64 |
| Return, 1 month / 3 months | −3.6% / −12.3% |
| Return, 1 year / 3 years | −10.4% / +35.8% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 17.5% |
| Worst drawdown (1 year) | -17.3% |
| Average daily value traded | 1.70M EUR |
| Dividend yield | 9.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Carmila is a French property company that owns and manages shopping centres, mainly retail galleries attached to Carrefour hypermarkets. Its centres bring together supermarkets, everyday shops, restaurants and services, and the company works with retailers and local communities to keep these locations active and well maintained. Carmila is based in France and operates a portfolio of shopping centres in France and other European countries, earning rental income from the merchants who occupy its premises.
The shares are listed on the Euronext Paris in France under the code CARM, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Carmila SA (CARM) trades on the Euronext Paris in France. It last closed at EUR 14.44 on 22 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 141 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.4% and over the last three months it fell 12.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 53 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -8.7% | ||
| From 52-week high | -22.0% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -12.3% | ||
| 6-month return | -11.1% | ||
| 12-month return, skipping the last month | -7.1% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 17.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.3% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 1.70M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 75 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 9.4% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −0.1% |
|---|---|
| 1 month | −3.6% |
| 3 months | −12.3% |
| 6 months | −11.1% |
| 1 year | −10.4% |
| 3 years | +35.8% |
| 5 years | +56.3% |
Signals
| 50-day / 200-day average | 15.16 / 15.82 |
|---|---|
| Golden / death cross (60 days) | Death, 15 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.26 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 May 2026 | EUR 1.3600 |
| 19 May 2025 | EUR 1.2500 |
| 29 Apr 2024 | EUR 1.2000 |
| 15 May 2023 | EUR 1.1700 |
| 23 May 2022 | EUR 1.0000 |
| 24 May 2021 | EUR 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.